EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2019 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2019 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Syndax Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 9th, 2017 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 9th, 2017 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Conatus Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 5th, 2020 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 5th, 2020 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Conatus Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 5th, 2015 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 5th, 2015 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of EpiZyme, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
Exhibit B LOCK-UP LETTER AGREEMENTLock-Up Letter Agreement • February 18th, 2011 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 18th, 2011 Company IndustryBARCLAYS CAPITAL INC. PIPER JAFFRAY & CO. As Representatives of the several Underwriters named in Schedule I of the Underwriting Agreement, c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Syndax Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 6th, 2018 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 6th, 2018 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Conatus Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 10th, 2016 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 10th, 2016 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Chiasma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2021 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Chiasma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 2nd, 2018 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 2nd, 2018 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Chiasma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2014 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2014 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of EpiZyme, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
Exhibit A LOCK-UP LETTER AGREEMENTLock-Up Letter Agreement • November 29th, 2011 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledNovember 29th, 2011 Company IndustryBarclays Capital Inc. Jefferies & Company, Inc. As Representatives of the several Underwriters named in Schedule I of the Underwriting Agreement, c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Ladies and Gentlemen:
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 5th, 2020 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 5th, 2020 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Chiasma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 2nd, 2018 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 2nd, 2018 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Syndax Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 10th, 2016 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 10th, 2016 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Conatus Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • February 9th, 2017 • MPM BioVentures IV QP LP • Pharmaceutical preparations
Contract Type FiledFebruary 9th, 2017 Company IndustryIn accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Syndax Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.